Skip to main content
Signal8

Functional Brands Inc. Announces Launch of GLP-Squared Injection

$MEHAPress releaseMay 6, 2026, 8:00 AM ETRead the release

Functional Brands announced the launch of GLP-Squared Injection, a proprietary dual-peptide formulation combining Semaglutide and Tirzepatide, available exclusively on its Tru2u.health platform. The new injectable is designed as a clinician-supervised metabolic therapy to provide amplified appetite regulation and glycemic control compared to single-agent products.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    MEHA: Functional Brands Inc. Announces Launch of GLP-Squared Injection — AI Analysis | Signal8